<p>Korro Bio, Inc.（纳斯达克代码：KRRO - 获取免费报告）的股票在目前覆盖该股票的十家研究公司中获得了平均 “持有” 的推荐，MarketBeat 报道称。一位分析师给予该股票卖出评级，七位分析师给予持有评级，另外两位分析师给予买入评级。在过去一年中，对该股票发布评级的券商的平均 12 个月目标价为 66.50 美元。</p>
<ul>
<li>三只可能因欧洲银行降息而上涨的股票</li>
</ul>
<p>KRRO 已成为几份研究报告的主题。Chardan Capital 在 1 月 29 日的报告中将 Korro Bio 的评级从 “中性” 上调至 “买入”，并设定了 15.00 美元的目标价。Jones Trading 在 11 月 14 日的研究报告中将 Korro Bio 的评级从 “买入” 下调至 “持有”。HC Wainwright 在 11 月 13 日的研究报告中重申了对 Korro Bio 股票的 “中性” 评级。Weiss Ratings 在 1 月 9 日的研究报告中重申了对 Korro Bio 股票的 “卖出（d-）” 评级。最后，Wall Street Zen 在 12 月 13 日的研究报告中将 Korro Bio 股票的评级从 “持有” 下调至 “卖出”。</p>
<p><strong>阅读我们关于 Korro Bio 的最新报告</strong></p>
<h2>Korro Bio 股票上涨 8.9%</h2>
<p>Korro Bio 股票在周五开盘时为 12.57 美元。Korro Bio 的 52 周低点为 5.20 美元，52 周高点为 55.89 美元。该公司的 50 日移动平均线为 8.97 美元，200 日移动平均线为 21.17 美元。该公司的市值为 1.1841 亿美元，市盈率为-1.34，贝塔值为 2.99。</p>
<p>Korro Bio（纳斯达克代码：KRRO - 获取免费报告）最近在 11 月 12 日发布了其财报。该公司报告季度每股收益（EPS）为（1.92 美元），超出市场共识预期的（2.61 美元）0.69 美元。Korro Bio 的净利润率为-1,199.53%，股本回报率为-68.87%。该季度的收入为 109 万美元，而分析师的预期为 41 万美元。整体来看，研究分析师预计 Korro Bio 在当前财政年度的每股收益将为-9.52。</p>
<h2>对 Korro Bio 的对冲基金看法</h2>
<p>机构投资者最近增加或减少了对该股票的持股。TCG Crossover Management LLC 在第三季度购买了价值 19,937,000 美元的 Korro Bio 新头寸。摩根大通在第三季度将其在 Korro Bio 的持股增加了 6,185.5%。摩根大通现在拥有 199,249 股该公司的股票，价值 9,542,000 美元，此前在上个季度又购买了 196,079 股。Schonfeld Strategic Advisors LLC 在第三季度收购了价值约 4,319,000 美元的 Korro Bio 新股份。Raymond James Financial Inc. 在第三季度将其在 Korro Bio 的持股增加了 78.6%。Raymond James Financial Inc. 现在拥有 148,971 股该公司的股票，价值 7,134,000 美元，此前在上个季度又购买了 65,579 股。最后，Emerald Mutual Fund Advisers Trust 在第三季度收购了价值 2,821,000 美元的 Korro Bio 新股份。机构投资者和对冲基金持有该公司 13.18% 的股份。</p>
<h2>Korro Bio 公司简介</h2>
<p>（获取免费报告）</p>
<p>Korro Bio, Inc 是一家临床阶段的生物技术公司，专注于利用先进的蛋白质工程和合成生物学开发新型酶疗法和活微生物治疗。该公司的专有平台整合了定向进化、高通量筛选和计算设计，以优化生物催化剂，适用于广泛的应用。通过将机器学习与实验生物学相结合，Korro Bio 力求加速下一代稀有遗传疾病和复杂代谢疾病治疗的发现和开发。</p>
<p>该公司的产品管线包括工程化酶疗法和活性生物治疗。</p>
<h2>了解更多</h2>
<ul>
<li>五只我们更看好的股票比 Korro Bio 更好</li>
<li>新法案：国会批准数字美元的设立？</li>
<li>对人工智能未来的 6.5 亿美元押注</li>
<li>华尔街害怕的黄金图表……</li>
<li>特朗普的人工智能秘密：比英伟达快 100 倍</li>
<li>你的银行账户不再安全</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9S1JSTw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9S1JSTw"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Korro Bio 吗？</h2>
<p>在你考虑投资 Korro Bio 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前立即购买……而 Korro Bio 并不在名单上。</p>
<p>虽然 Korro Bio 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

KRRO

纳斯达克生物科技指数 ETF - iShares Nasdaq

IBBQ

纽交所高增长板生物技术指数 ETF - First Trust

标普生物技术 ETF - SPDR

生物科技 ETF - VanEck Vectors

2 倍做多纳斯达克生物技术 ETF - ProShares

医药突破 ETF - ALPS

动态生物技术与基因组 ETF - Invesco

<p>Korro Bio, Inc.（纳斯达克代码：KRRO）获得了十家研究机构的平均评级为 “持有”。一位分析师将其评级为卖出，七位分析师评级为持有，二位分析师评级为买入。平均目标价格为 66.50 美元。最近的报告包括 Chardan Capital 将评级从 “中性” 上调至 “买入”，以及 Jones Trading 将评级从 “买入” 下调至 “持有”。Korro Bio 的股票开盘价为 12.57 美元，52 周范围为 5.20 美元至 55.89 美元。该公司报告每股收益为（1.92 美元），超出预期，收入为 109 万美元</p>

<p>Shares of Korro Bio, Inc. (NASDAQ:KRRO - Get Free Report) have earned an average recommendation of &#34;Hold&#34; from the ten research firms that are presently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and two have assigned a buy rating to the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $66.50.</p>
<div class="lb-trans"><p>Korro Bio, Inc.（纳斯达克代码：KRRO - 获取免费报告）的股票在目前覆盖该股票的十家研究公司中获得了平均 “持有” 的推荐，MarketBeat 报道称。一位分析师给予该股票卖出评级，七位分析师给予持有评级，另外两位分析师给予买入评级。在过去一年中，对该股票发布评级的券商的平均 12 个月目标价为 66.50 美元。</p>
</div><ul>
<li>3 Stocks That Could Rise on European Bank Interest Rate Cuts</li>
</ul>
<div class="lb-trans"><ul>
<li>三只可能因欧洲银行降息而上涨的股票</li>
</ul>
</div><p>KRRO has been the topic of several research reports. Chardan Capital raised Korro Bio from a &#34;neutral&#34; rating to a &#34;buy&#34; rating and set a $15.00 price objective on the stock in a report on Thursday, January 29th. Jones Trading cut Korro Bio from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a research report on Friday, November 14th. HC Wainwright reaffirmed a &#34;neutral&#34; rating on shares of Korro Bio in a research report on Thursday, November 13th. Weiss Ratings reiterated a &#34;sell (d-)&#34; rating on shares of Korro Bio in a research note on Friday, January 9th. Finally, Wall Street Zen lowered shares of Korro Bio from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research report on Saturday, December 13th.</p>
<div class="lb-trans"><p>KRRO 已成为几份研究报告的主题。Chardan Capital 在 1 月 29 日的报告中将 Korro Bio 的评级从 “中性” 上调至 “买入”，并设定了 15.00 美元的目标价。Jones Trading 在 11 月 14 日的研究报告中将 Korro Bio 的评级从 “买入” 下调至 “持有”。HC Wainwright 在 11 月 13 日的研究报告中重申了对 Korro Bio 股票的 “中性” 评级。Weiss Ratings 在 1 月 9 日的研究报告中重申了对 Korro Bio 股票的 “卖出（d-）” 评级。最后，Wall Street Zen 在 12 月 13 日的研究报告中将 Korro Bio 股票的评级从 “持有” 下调至 “卖出”。</p>
</div><p><strong>Read Our Latest Report on Korro Bio</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 Korro Bio 的最新报告</strong></p>
</div><h2>Korro Bio Stock Up 8.9%</h2>
<div class="lb-trans"><h2>Korro Bio 股票上涨 8.9%</h2>
</div><p>Shares of Korro Bio stock opened at $12.57 on Friday. Korro Bio has a 52 week low of $5.20 and a 52 week high of $55.89. The firm's 50 day moving average is $8.97 and its two-hundred day moving average is $21.17. The firm has a market capitalization of $118.41 million, a P/E ratio of -1.34 and a beta of 2.99.</p>
<div class="lb-trans"><p>Korro Bio 股票在周五开盘时为 12.57 美元。Korro Bio 的 52 周低点为 5.20 美元，52 周高点为 55.89 美元。该公司的 50 日移动平均线为 8.97 美元，200 日移动平均线为 21.17 美元。该公司的市值为 1.1841 亿美元，市盈率为-1.34，贝塔值为 2.99。</p>
</div><p>Korro Bio (NASDAQ:KRRO - Get Free Report) last issued its earnings results on Wednesday, November 12th. The company reported ($1.92) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.61) by $0.69. Korro Bio had a negative net margin of 1,199.53% and a negative return on equity of 68.87%. The business had revenue of $1.09 million during the quarter, compared to analysts' expectations of $0.41 million. As a group, research analysts expect that Korro Bio will post -9.52 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Korro Bio（纳斯达克代码：KRRO - 获取免费报告）最近在 11 月 12 日发布了其财报。该公司报告季度每股收益（EPS）为（1.92 美元），超出市场共识预期的（2.61 美元）0.69 美元。Korro Bio 的净利润率为-1,199.53%，股本回报率为-68.87%。该季度的收入为 109 万美元，而分析师的预期为 41 万美元。整体来看，研究分析师预计 Korro Bio 在当前财政年度的每股收益将为-9.52。</p>
</div><h2>Hedge Funds Weigh In On Korro Bio</h2>
<div class="lb-trans"><h2>对 Korro Bio 的对冲基金看法</h2>
</div><p>Institutional investors have recently added to or reduced their stakes in the stock. TCG Crossover Management LLC purchased a new position in Korro Bio in the 3rd quarter valued at $19,937,000. JPMorgan Chase &amp; Co. grew its holdings in Korro Bio by 6,185.5% in the third quarter. JPMorgan Chase &amp; Co. now owns 199,249 shares of the company's stock valued at $9,542,000 after purchasing an additional 196,079 shares during the last quarter. Schonfeld Strategic Advisors LLC acquired a new stake in Korro Bio in the 3rd quarter valued at about $4,319,000. Raymond James Financial Inc. grew its position in shares of Korro Bio by 78.6% in the third quarter. Raymond James Financial Inc. now owns 148,971 shares of the company's stock valued at $7,134,000 after purchasing an additional 65,579 shares during the last quarter. Finally, Emerald Mutual Fund Advisers Trust acquired a new stake in Korro Bio during the 3rd quarter valued at $2,821,000. Institutional investors and hedge funds own 13.18% of the company's stock.</p>
<div class="lb-trans"><p>机构投资者最近增加或减少了对该股票的持股。TCG Crossover Management LLC 在第三季度购买了价值 19,937,000 美元的 Korro Bio 新头寸。摩根大通在第三季度将其在 Korro Bio 的持股增加了 6,185.5%。摩根大通现在拥有 199,249 股该公司的股票，价值 9,542,000 美元，此前在上个季度又购买了 196,079 股。Schonfeld Strategic Advisors LLC 在第三季度收购了价值约 4,319,000 美元的 Korro Bio 新股份。Raymond James Financial Inc. 在第三季度将其在 Korro Bio 的持股增加了 78.6%。Raymond James Financial Inc. 现在拥有 148,971 股该公司的股票，价值 7,134,000 美元，此前在上个季度又购买了 65,579 股。最后，Emerald Mutual Fund Advisers Trust 在第三季度收购了价值 2,821,000 美元的 Korro Bio 新股份。机构投资者和对冲基金持有该公司 13.18% 的股份。</p>
</div><h2>Korro Bio Company Profile</h2>
<div class="lb-trans"><h2>Korro Bio 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Korro Bio, Inc is a clinical-stage biotechnology company focused on harnessing advanced protein engineering and synthetic biology to develop novel enzyme therapies and live microbial therapeutics. The company's proprietary platform integrates directed evolution, high-throughput screening and computational design to optimize biological catalysts for a wide range of applications. By combining machine learning with experimental biology, Korro Bio seeks to accelerate the discovery and development of next-generation treatments for rare genetic disorders and complex metabolic diseases.</p>
<div class="lb-trans"><p>Korro Bio, Inc 是一家临床阶段的生物技术公司，专注于利用先进的蛋白质工程和合成生物学开发新型酶疗法和活微生物治疗。该公司的专有平台整合了定向进化、高通量筛选和计算设计，以优化生物催化剂，适用于广泛的应用。通过将机器学习与实验生物学相结合，Korro Bio 力求加速下一代稀有遗传疾病和复杂代谢疾病治疗的发现和开发。</p>
</div><p>The company's pipeline features both engineered enzyme therapeutics and live biotherapeutics.</p>
<div class="lb-trans"><p>该公司的产品管线包括工程化酶疗法和活性生物治疗。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than Korro Bio</li>
<li>NEW LAW: Congress Approves Setup For Digital Dollar?</li>
<li>The $650 Million Bet on AI's Future</li>
<li>The gold chart Wall Street is terrified of…</li>
<li>Trump’s AI Secret: 100X Faster Than Nvidia</li>
<li>Your Bank Account Is No Longer Safe</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票比 Korro Bio 更好</li>
<li>新法案：国会批准数字美元的设立？</li>
<li>对人工智能未来的 6.5 亿美元押注</li>
<li>华尔街害怕的黄金图表……</li>
<li>特朗普的人工智能秘密：比英伟达快 100 倍</li>
<li>你的银行账户不再安全</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9S1JSTw" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=KRRO"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Korro Bio Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Korro Bio 吗？</h2>
</div><p>Before you consider Korro Bio, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑投资 Korro Bio 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Korro Bio wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前立即购买……而 Korro Bio 并不在名单上。</p>
</div><p>While Korro Bio currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Korro Bio 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Korro Bio, Inc. (NASDAQ:KRRO) Given Average Rating of "Hold" by Brokerages

Market Beat

Korro Bio

Invesco Nasdaq Biotechnology ETF

Korro Bio, Inc.（纳斯达克股票代码：KRRO）被券商给予 “持有” 评级的平均评价